Since reports that blood cancer response rates to T cells carrying chimeric antigen receptors (CARs) exceed 80%, investors have been laying bets on CAR-T cell approaches. In August, the first two therapies hit European markets in a head-to-head race to be the number one next-gen cancer therapy. So will CAR-T cell treatment really take pole position? Or will alternatives like TCR-based cell therapy or multivalent antibody-T cell engagers leave them in the dust?
Eppendorf BioFlo® 120 Bioprocess Control Station
ProductsThe flexible BioFlo 120 bioreactor/fermentor control station is capable of microbial fermentation as well as mammalian cell culture applications.
Boehringer and Epizyme enter US$300m deal
Latest NewsBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
Latest NewsResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
Hox Therapeutics appoints Karl Keegan as CEO
AppointmentsHox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
Latest NewsAstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Amal bags €21.2m financing
Latest NewsSwiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.
Antibiotic resistance spreading across Europe
Latest NewsAntimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.
Liquid biopsy: size matters
Latest NewsA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).
Themis postpones IPO
Latest NewsOne week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its IPO.
CARs right on track
BackgroundSince reports that blood cancer response rates to T cells carrying chimeric antigen receptors (CARs) exceed 80%, investors have been laying bets on CAR-T cell approaches. In August, the first two therapies hit European markets in a head-to-head race to be the number one next-gen cancer therapy. So will CAR-T cell treatment really take pole position? Or will alternatives like TCR-based cell therapy or multivalent antibody-T cell engagers leave them in the dust?